ShareProphets : keywords

SBTX

PREMIUM CONTENT

SkinBioTherapeutics – SkinBiotix additional formal studies, a short-term delay but enhanced outlook: STRONG BUY

SkinBioTherapeutics (SBTX) has announced on its AxisBiotix-Ps (psoriasis) product that it has commenced sales in Spain aided by the launch of a regional website and on its skin care active ingredient SkinBiotix that partner, cosmetics business of FTSE-100 Croda (CRDA), Sederma has noted ‘exciting’ additional benefits which means delays in monetisation. Is that good news or bad?

Subscribe to ShareProphets to access Premium Content

By Tom Winnifrith & Steve Moore
136 days ago

SBTX

PREMIUM CONTENT

SkinBioTherapeutics – interims, Mr Market has it wrong. Strong Buy

SkinBioTherapeutics (SBTX) has announced results for its half-year ended 31^st December 2022 and the shares have been marked down in response. Mr Market has got it wrong and this is a Strong Buy.

Subscribe to ShareProphets to access Premium Content

By HotStockRockets
180 days ago

SBTX

PREMIUM CONTENT

SkinBioTherapeutics – no-one watching o’clock results and equity raise, what’s the outlook from here?

SkinBioTherapeutics (SBTX) has announced no-one watching o’clock (4:30pm) results for its year ended 30^th June 2022, with CEO Stuart Ashman stating “this financial year has been a mixed one for the group”. With the results coming with a potentially £3.5 million equity raise (albeit including an up to £1 million “retail offer”) at 16p per share, we’ve got some other words for it but where does this all leave the company now?

Subscribe to ShareProphets to access Premium Content

By Tom Winnifrith & Steve Moore
283 days ago

SBTX

PREMIUM CONTENT

SkinBioTherapeutics – “Business update”, expect shares to respond positively on further updates soon: BUY!

SkinBioTherapeutics (SBTX) has published a “Business update” announcement including that it has now progressed to the second phase of its AxisBiotix-Ps food supplement for psoriasis product commercialisation strategy and that the SkinBiotix active ingredient project with Sederma is on track. Sounds good!